Wave makes $100M public offering after dosing first subjects with GSK-partnered RNA editing drug
Wave Life Sciences is offering $100 million in shares just shortly after it started testing its first RNA editing candidate in healthy subjects, which triggered a payout from Big Pharma partner GSK.
The biotech announced the public offering on Wednesday, the same day it began dosing healthy volunteers with its alpha-1 antitrypsin deficiency (AATD) treatment candidate, WVE-006. Wave’s RestorAATion program comprises two trials — RestorAATion-1 is focused on healthy subjects, and RestorAATion-2 is enrolling AATD patients with a homozygous PiZZ mutation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.